Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease - A randomized study

Parkinsonism and Related Disorders

Volumn 19, Issue 7, 2013, Pages 670-675

  Rios Romenets, S ^a   Creti, L ^b   Fichten, C ^b   Bailes, S ^b   Libman, E ^b   Pelletier, A ^c   Postuma, R B ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Insomnia; Parkinson's disease; Treatment

Indexed keywords

DOXEPIN; PLACEBO;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; INSOMNIA; INSOMNIA SEVERITY INDEX; MALE; MONTREAL COGNITIVE ASSESSMENT; NAUSEA; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSON DISEASE QUESTIONNAIRE 39; PHOTOTHERAPY; PITTSBURGH SLEEP QUALITY INDEX; POSITIONAL DIZZINESS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCOPA; SCORING SYSTEM; SLEEP; TREATMENT OUTCOME;

ACTIGRAPHY; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COGNITIVE THERAPY; DOXEPIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84878230600     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.03.003     Document Type: Article

References (30)

1. Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep Med 2007 Dec, 8(Suppl. 4):S27-S34.
2. Adler C.H., Thorpy M.J. Sleep issues in Parkinson's disease. Neurology 2005 Jun 28, 64(12 Suppl. 3):S12-S20.
3. Stavitsky K., Neargarder S., Bogdanova Y., McNamara P., Cronin-Golomb A. The impact of sleep quality on cognitive functioning in Parkinson's disease. JInt Neuropsychol Soc 2012 Jan, 18(1):108-117.
4. Menza M., Dobkin R.D., Marin H., Gara M., Bienfait K., Dicke A., et al. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord 2010 Aug 15, 25(11):1708-1714.
5. Dowling G.A., Mastick J., Colling E., Carter J.H., Singer C.M., Aminoff M.J. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005 Sep, 6(5):459-466.
6. Ebben M.R., Spielman A.J. Non-pharmacological treatments for insomnia. JBehav Med 2009 Jun, 32(3):244-254.
7. Irwin M.R., Cole J.C., Nicassio P.M. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol 2006 Jan, 25(1):3-14.
8. Bootzin R.R., Perlis M.L. Nonpharmacologic treatments of insomnia. JClin Psychiatry 1992 Jun, 53(Suppl.):37-41.
9. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 Mar-Apr, 24(2):197-211.
10. Pal P.K., Calne S., Samii A., Fleming J.A. Areview of normal sleep and its disturbances in Parkinson's disease. Parkinsonism Relat Disord 1999 Apr, 5(1-2):1-17.
11. Scharf M., Rogowski R., Hull S., Cohn M., Mayleben D., Feldman N., et al. Efficacy and safety of doxepin 1mg, 3mg, and 6mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. JClin Psychiatry 2008 Oct, 69(10):1557-1564.
12. Roth T., Rogowski R., Hull S., Schwartz H., Koshorek G., Corser B., et al. Efficacy and safety of doxepin 1mg, 3mg, and 6mg in adults with primary insomnia. Sleep 2007, 30(11):1555-1561.
13. Martinez-Martin P., Visser M., Rodriguez-Blazquez C., Marinus J., Chaudhuri K.R., van Hilten J.J. SCOPA-sleep and PDSS: two scales for assessment of sleep disorder in Parkinson's disease. Mov Disord 2008 Sep 15, 23(12):1681-1688.
14. Hogl B., Arnulf I., Comella C., Ferreira J., Iranzo A., Tilley B., et al. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord 2010 Dec 15, 25(16):2704-2716.
15. Bastien C.H., Vallieres A., Morin C.M. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001 Jul, 2(4):297-307.
16. Chaudhuri K.R., Pal S., DiMarco A., Whately-Smith C., Bridgman K., Mathew R., et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. JNeurol Neurosurg Psychiatry 2002 Dec, 73(6):629-635.
17. Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989 May, 28(2):193-213.
18. Guy W. ECDEU assessment manual for psychopharmacology: revised 1976, vol. 218-222:218-222. US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs.
19. Stavitsky K., Saurman J.L., McNamara P., Cronin-Golomb A. Sleep in Parkinson's disease: a comparison of actigraphy and subjective measures. Parkinsonism Relat Disord 2010 May, 16(4):280-283.
20. Mastin D.F., Bryson J., Corwyn R. Assessment of sleep hygiene using the Sleep Hygiene Index. JBehav Med 2006 Jun, 29(3):223-227.
21. Morin C.M., Vallieres A., Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep 2007 Nov, 30(11):1547-1554.
22. Garber C.E., Friedman J.H. Effects of fatigue on physical activity and function in patients with Parkinson's disease. Neurology 2003, 60(7):1119-1124.
23. Merino-Andreu M., Arnulf I., Konofal E., Derenne J.P., Agid Y. Unawareness of naps in Parkinson's disease and in disorders with excessive daytime sleepiness. Neurology 2003 May 13, 60(9):1553-1554.
24. Schrag A., Barone P., Brown R.G., Leentjens A.F., McDonald W.M., Starkstein S., et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007 Jun 15, 22(8):1077-1092.
25. Peto V., Jenkinson C., Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. JNeurol 1998 May, 245(Suppl. 1):S10-S14.
26. Nasreddine Z.S., Phillips N.A., Bedirian V., Charbonneau S., Whitehead V., Collin I., et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. JAm Geriatr Soc 2005 Apr, 53(4):695-699.
27. Cimolai N. Zopiclone: is it a pharmacologic agent for abuse?. Can Fam Physician 2007 Dec, 53(12):2124-2129.
28. Terman M., Terman J.S. Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. CNS Spectr 2005 Aug, 10(8):647-663. [quiz 72].
29. Bordet R., Devos D., Brique S., Touitou Y., Guieu J.D., Libersa C., et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 2003 Mar-Apr, 26(2):65-72.
30. Willis G.L., Moore C., Armstrong S.M. Ahistorical justification for and retrospective analysis of the systematic application of light therapy in Parkinson's disease. Rev Neurosci 2012, 23(2):199-226.